Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CYTH Stock Summary
Top 10 Correlated ETFs
CYTH
In the News
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer and Joshua Fine, Chief Financial Officer of Cyclo Therapeutics will present at the 8th Annual Dawson James Conference being held in Jupiter, FL on Thursday,.
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
GAINESVILLE, Fla.--( BUSINESS WIRE )--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 11:00 AM ET.
Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-
Cyclo Therapeutics to Present at the China NPC Association Meeting
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will present at the 2022 China Nieman Pick Medical Exchange & Sixth Patient Association being held August 13, 2022 in Xiamen,
Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it will participate at the 30th Annual NNPDF Family Support & Medical Conference in conjunction with the INPDA Biennial Meeting being held July 28-31, 2022, in Orlando, FL. “Perspectives from
Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will present at the World Orphan Drug Congress USA 2022 being held July 11-13, 2022 in Boston, MA. During the session, Dr. Kjems w
Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Professor Caroline Hastings, MD will present at the 2022 NPC Conference hosted by the Australian NPC Disease Foundation being held virtually June 23-24, 2022. Details of the presentation are as f
Cyclo Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022 at 3:20 PM ET. In addition to the presentation, ma
Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the poster presentation of its ongoing pivotal Phase 3 study, TransportNPC™ at the 18th Annual WORLDSymposium 2022, a leading medical and scientific conference for professionals working to advance und
Cyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Virtual Investor 2022 Top Picks Conference on Thursday, January 27, 2022 at 10:00 AM ET. As part of the virtual ev
CYTH Financial details
CYTH Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.83 | 0.56 | 0.25 | 0.22 | 0.07 | |
Net income per share | -6.31 | -5.58 | -2.25 | -2.4 | -1.23 | |
Operating cash flow per share | -5.42 | -5.34 | -2.36 | -2.37 | -0.99 | |
Free cash flow per share | -5.42 | -5.37 | -2.36 | -2.38 | -0.99 | |
Cash per share | 2.29 | 8.03 | 2.61 | 0.24 | 0.57 | |
Book value per share | 0.77 | 6.54 | 2.46 | 0.12 | 0.29 | |
Tangible book value per share | 0.77 | 6.54 | 2.46 | 0.12 | 0.29 | |
Share holders equity per share | 0.77 | 6.54 | 2.46 | 0.12 | 0.29 | |
Interest debt per share | 0.04 | 0.12 | 0.03 | -0.02 | 0.06 | |
Market cap | 41.33M | 6.96M | 23.76M | 9.04M | 25.96M | |
Enterprise value | 38.6M | -5.7M | 7.32M | 7.5M | 17.75M | |
P/E ratio | -5.39 | -0.78 | -1.66 | -0.59 | -1.29 | |
Price to sales ratio | 41.04 | 7.7 | 14.98 | 6.57 | 24.12 | |
POCF ratio | -6.27 | -0.81 | -1.58 | -0.6 | -1.6 | |
PFCF ratio | -6.27 | -0.81 | -1.58 | -0.6 | -1.6 | |
P/B Ratio | 44.16 | 0.67 | 1.52 | 12.31 | 5.46 | |
PTB ratio | 44.16 | 0.67 | 1.52 | 12.31 | 5.46 | |
EV to sales | 38.32 | -6.3 | 4.62 | 5.45 | 16.49 | |
Enterprise value over EBITDA | -5.33 | 0.64 | -0.51 | -0.48 | -0.89 | |
EV to operating cash flow | -5.86 | 0.67 | -0.49 | -0.5 | -1.1 | |
EV to free cash flow | -5.86 | 0.66 | -0.49 | -0.5 | -1.1 | |
Earnings yield | -0.19 | -1.28 | -0.6 | -1.69 | -0.77 | |
Free cash flow yield | -0.16 | -1.24 | -0.63 | -1.67 | -0.62 | |
Debt to equity | 0.06 | 0.02 | 0.01 | 0 | 0.22 | |
Debt to assets | 0.01 | 0.01 | 0.01 | 0 | 0.08 | |
Net debt to EBITDA | 0.38 | 1.41 | 1.16 | 0.1 | 0.41 | |
Current ratio | 1.26 | 3.83 | 5.07 | 1.19 | 1.45 | |
Interest coverage | 0 | 0 | 0 | 103.76 | 0 | |
Income quality | 0.87 | 0.96 | 1.05 | 0.98 | 0.81 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.41 | 4.07 | 4.1 | 5.67 | 5.26 | |
Research and developement to revenue | 4.83 | 6.75 | 5.77 | 6.54 | 13.18 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.01 | 0 | 0 | 0 | |
Capex to revenue | 0 | -0.06 | -0.01 | -0.01 | 0 | |
Capex to depreciation | -0.23 | -4.16 | -1.34 | -0.77 | -0.13 | |
Stock based compensation to revenue | 0.43 | 0.3 | 0.3 | 0.37 | 0.68 | |
Graham number | 10.46 | 28.65 | 11.15 | 2.5 | 2.84 | |
ROIC | -7.23 | -0.84 | -0.9 | -21.02 | -3.45 | |
Return on tangible assets | -1.87 | -0.63 | -0.73 | -3.62 | -1.51 | |
Graham Net | -0.11 | 5.82 | 2.09 | -0.28 | 0.06 | |
Working capital | 816.95K | 10.38M | 15.61M | 677.89K | 3.85M | |
Tangible asset value | 935.98K | 10.45M | 15.67M | 734.54K | 4.76M | |
Net current asset value | 780.82K | 10.31M | 15.59M | 677.89K | 3.83M | |
Invested capital | 0.06 | 0.02 | 0.01 | 0 | 0.22 | |
Average receivables | 149.99K | 147.14K | 325.44K | 297.04K | 88.69K | |
Average payables | 2.53M | 3.33M | 3.61M | 3.58M | 4.17M | |
Average inventory | 329.58K | 240.27K | 232.67K | 240.96K | 254.42K | |
Days sales outstanding | 66.13 | 45.17 | 124.08 | 14.59 | 41.5 | |
Days payables outstanding | 15.11K | 19.47K | 8.6K | 9.14K | 508.42 | |
Days of inventory on hand | 1.17K | 1.31K | 531.87 | 668.61 | 26.63 | |
Receivables turnover | 5.52 | 8.08 | 2.94 | 25.02 | 8.8 | |
Payables turnover | 0.02 | 0.02 | 0.04 | 0.04 | 0.72 | |
Inventory turnover | 0.31 | 0.28 | 0.69 | 0.55 | 13.71 | |
ROE | -8.2 | -0.85 | -0.91 | -20.8 | -4.22 | |
Capex per share | 0 | -0.03 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.03 | 0.01 | 0.01 | 0.03 | 0.01 | |
Net income per share | -0.76 | -0.46 | -0.33 | -0.29 | -0.23 | |
Operating cash flow per share | -0.43 | -0.4 | -0.25 | -0.25 | -0.17 | |
Free cash flow per share | -0.43 | -0.4 | -0.25 | -0.25 | -0.17 | |
Cash per share | 0.24 | 0.08 | 0.06 | 0.11 | 0.37 | |
Book value per share | 0.12 | -0.04 | -0.11 | -0.07 | 0.19 | |
Tangible book value per share | 0.12 | -0.04 | -0.11 | -0.07 | 0.19 | |
Share holders equity per share | 0.12 | -0.04 | -0.11 | -0.07 | 0.19 | |
Interest debt per share | 0.03 | 0 | 0 | 0 | 0.04 | |
Market cap | 9.04M | 9.24M | 22.33M | 22.99M | 39.54M | |
Enterprise value | 7.5M | 8.38M | 21.53M | 21.24M | 31.33M | |
P/E ratio | -0.47 | -0.46 | -1.2 | -1.2 | -1.75 | |
Price to sales ratio | 48.41 | 60.65 | 190.64 | 46.4 | 126.98 | |
POCF ratio | -3.29 | -2.11 | -6.42 | -5.69 | -9.21 | |
PFCF ratio | -3.31 | -2.11 | -6.42 | -5.69 | -9.2 | |
P/B Ratio | 12.31 | -21.06 | -15.04 | -21.84 | 8.31 | |
PTB ratio | 12.31 | -21.06 | -15.04 | -21.84 | 8.31 | |
EV to sales | 40.14 | 54.99 | 183.87 | 42.86 | 100.61 | |
Enterprise value over EBITDA | -1.51 | -1.68 | -4.66 | -4.46 | -5.56 | |
EV to operating cash flow | -2.73 | -1.92 | -6.19 | -5.25 | -7.29 | |
EV to free cash flow | -2.75 | -1.92 | -6.19 | -5.25 | -7.29 | |
Earnings yield | -0.53 | -0.54 | -0.21 | -0.21 | -0.14 | |
Free cash flow yield | -0.3 | -0.47 | -0.16 | -0.18 | -0.11 | |
Debt to equity | 0 | -0.12 | -0.03 | -0.04 | 0.22 | |
Debt to assets | 0 | 0.01 | 0.01 | 0.01 | 0.08 | |
Net debt to EBITDA | 0.31 | 0.17 | 0.17 | 0.37 | 1.46 | |
Current ratio | 1.19 | 0.89 | 0.75 | 0.83 | 1.45 | |
Interest coverage | -26.88 | 106.53K | 0 | 0 | 0 | |
Income quality | 0.55 | 0.87 | 0.75 | 0.85 | 0.76 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 10.45 | 11.44 | 10.88 | 3.08 | 4.49 | |
Research and developement to revenue | 17.05 | 22.3 | 27.07 | 7 | 13.31 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | -0.01 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0.08 | 0 | 0 | 0 | -0.01 | |
Capex to depreciation | 3.1 | 0 | 0 | 0 | -0.5 | |
Stock based compensation to revenue | 1.15 | 0.6 | 1.58 | 0.41 | 0.83 | |
Graham number | 1.4 | 0.64 | 0.89 | 0.66 | 0.99 | |
ROIC | -6.54 | 15.09 | 3.35 | 4.96 | -0.97 | |
Return on tangible assets | -1.14 | -1.22 | -1 | -0.85 | -0.43 | |
Graham Net | -0.28 | -0.31 | -0.36 | -0.28 | 0.04 | |
Working capital | 677.89K | -506.11K | -1.55M | -1.11M | 3.85M | |
Tangible asset value | 734.54K | -438.88K | -1.48M | -1.05M | 4.76M | |
Net current asset value | 677.89K | -542.64K | -1.58M | -1.14M | 3.83M | |
Invested capital | 0 | -0.12 | -0.03 | -0.04 | 0.22 | |
Average receivables | 224.78K | 93.11K | 109.81K | 196.08K | 213.07K | |
Average payables | 3.18M | 3.98M | 5.28M | 6.34M | 5.73M | |
Average inventory | 262.81K | 249.49K | 240.57K | 223.2K | 232.05K | |
Days sales outstanding | 26.49 | 77.49 | 67.92 | 55.18 | 35.37 | |
Days payables outstanding | 19.87K | 39.57K | 27.48K | 15.33K | 498.64 | |
Days of inventory on hand | 1.45K | 2.16K | 1.07K | 486.96 | 26.12 | |
Receivables turnover | 3.4 | 1.16 | 1.32 | 1.63 | 2.54 | |
Payables turnover | 0 | 0 | 0 | 0.01 | 0.18 | |
Inventory turnover | 0.06 | 0.04 | 0.08 | 0.18 | 3.45 | |
ROE | -6.55 | 11.41 | 3.12 | 4.53 | -1.19 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
CYTH Frequently Asked Questions
What is Cyclo Therapeutics, Inc. stock symbol ?
Cyclo Therapeutics, Inc. is a US stock , located in Gainesville of Fl and trading under the symbol CYTH
What is Cyclo Therapeutics, Inc. stock quote today ?
Cyclo Therapeutics, Inc. stock price is $1.4 today.
Is Cyclo Therapeutics, Inc. stock public?
Yes, Cyclo Therapeutics, Inc. is a publicly traded company.